Merck & Co., Inc. acquires Prometheus Biosciences, Inc. (2023)

Deal facts

Buyer: Merck & Co., Inc.
Target: Prometheus Biosciences, Inc.
Deal value: Not disclosed
Announced: 17 April 2023
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

16 Jun 2023CompletedClosed
Merck & Co., Inc. completes acquisition of Prometheus Biosciences, Inc.
Item 2.01 Completion of Acquisition or Disposition of Assets. On June 16, 2023 (the “Closing Date”), Prometheus Biosciences, Inc., a Delaware corporation (“Prometheus”), completed the previously announced merger of Splash Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and a wholly owned subsidiary of Merck & Co., Inc., a New Jersey corporation (“Merck”), with and into Prometheus (the “Mer
Source

OpinionExit Mode editorial

We see a clear signal in the completed acquisition of Prometheus Biosciences by Merck & Co. This deal, announced in April 2023, represents a classic going-private transaction where a large US healthcare incumbent moves to secure a smaller biotech asset with cash. The absence of any disclosed value in the public record is notable, yet the all-cash consideration structure removes the typical equity volatility that often clouds such negotiations. For the SME founder reading this, the mechanism here is straightforward: a major player identified a specific capability, agreed on terms, and paid in cash to take the company off the public market immediately.

The strategic logic is evident even without the price tag. Merck, a global giant, is not merely buying a product but acquiring a platform to bolster its internal pipeline. In the US healthcare sector, this type of consolidation often triggers rigorous competition reviews. While the deal has completed, the path to clearance likely involved scrutiny from the Federal Trade Commission regarding potential anti-trust issues. The use of cash as the sole consideration suggests the buyer wanted to avoid the complexities of a share-swap and the ongoing regulatory reporting requirements that come with maintaining a public listing. This is a clean exit for the target, bypassing the protracted integration dance of a merger of equals.

We think this deal underscores a vital lesson for founders in the biotech space. The market continues to reward specialized innovation that can be absorbed into a larger commercial engine. The fact that the transaction closed without a public valuation figure implies that the parties relied on private negotiations and bespoke earn-out structures or escrow arrangements to bridge any valuation gaps. The buyer accepted the risk of the asset's future performance in exchange for immediate control. This is a stark contrast to deals that rely on complex stock-based payments which dilute founder ownership over time.

Your takeaway this week is to audit your own cap table and identify which of your key milestones could justify a cash-only offer from a strategic buyer. Do not wait for a public valuation to prove your worth to a major incumbent. Prepare a one-page summary of your pipeline that highlights exactly how your technology solves a specific gap in a larger company's portfolio, then reach out to their corporate development team to test the waters for a potential going-private discussion.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2023 deals More going private deals More from Merck & Co., Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

5 May 2026CompletedHealthcare

Merck to acquire Terns Pharmaceuticals, Inc.

Merck and Terns Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Merck
Target: Terns Pharmaceuticals, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

27 April 2026CompletedHealthcare

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. entered the Exit Mode archive.

Buyer: BioMarin Pharmaceutical Inc.
Target: Amicus Therapeutics, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 April 2026CompletedHealthcare

Servier to acquire Day One Biopharmaceuticals, Inc.

Servier and Day One Biopharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Servier
Target: Day One Biopharmaceuticals, Inc.
Deal value: USD 2,500,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 March 2026CompletedHealthcare

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Aurinia Pharma U.S., Inc. and Kezar Life Sciences, Inc. entered the Exit Mode archive.

Buyer: Aurinia Pharma U.S., Inc.
Target: Kezar Life Sciences, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 March 2026CompletedHealthcare

Abbott to acquire Exact Sciences Corp

Abbott and Exact Sciences Corp entered the Exit Mode archive.

Buyer: Abbott
Target: Exact Sciences Corp
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history

Merck & Co., Inc.

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive

Merck & Co., Inc. to acquire Prometheus Biosciences, Inc.

Deal facts

Join Exit Mode Insider

Deal timeline

Browse adjacent archives

Similar deals

Merck to acquire Terns Pharmaceuticals, Inc.

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

Servier to acquire Day One Biopharmaceuticals, Inc.

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Abbott to acquire Exact Sciences Corp

Merck & Co., Inc.

How this page is built